Zoetis Inc. $ZTS Shares Sold by LGT Group Foundation

LGT Group Foundation cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 13.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 67,588 shares of the company’s stock after selling 10,130 shares during the quarter. LGT Group Foundation’s holdings in Zoetis were worth $9,932,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new stake in Zoetis in the second quarter valued at $809,491,000. Diamond Hill Capital Management Inc. purchased a new position in shares of Zoetis in the third quarter valued at $394,010,000. Corient Private Wealth LLC raised its stake in shares of Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after buying an additional 1,191,840 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Zoetis by 342.1% during the 3rd quarter. First Trust Advisors LP now owns 1,485,459 shares of the company’s stock worth $217,352,000 after buying an additional 1,149,467 shares during the last quarter. Finally, Impax Asset Management Group plc boosted its position in shares of Zoetis by 362.6% in the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after buying an additional 922,589 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.6%

Zoetis stock opened at $121.54 on Monday. The stock has a 50-day moving average price of $126.06 and a 200 day moving average price of $132.88. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The stock has a market cap of $51.31 billion, a PE ratio of 20.19, a P/E/G ratio of 1.85 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ZTS shares. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.